• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Juul Suspends U.S. Advertising, CEO Steps Down

by Mary Beth Nierengarten • September 27, 2019

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

In late September, Juul Labs, which manufactures flavored e-cigarettes, announced it would suspend all broadcast, print, and digital product advertising in the United States, and that its CEO Ken Burns would step down. The statement comes as regulators assess multiple cases of what appears to be a vaping-related lung disease.

You Might Also Like

  • COSM 2012: TRIO Guest of Honor Cautions against Physician Advertising
  • Pathology of Lung Disease Linked to Vaping
  • FDA Recalls Zantac
  • EMR and Advertising: Strange Bedfellows?

The FDA recently found Juul’s advertising campaign, which touted its vaping products as safer alternatives to cigarettes, to be illegal because of the lack of supportive scientific evidence. On September 9, the FDA issued a warning letter to Juul stating that it needs to correct its marketing or risk being fined or having its vaping products seized.

In its September statement, Juul also said it would not push back on a Trump administration plan to pull fruit-flavored vaping products from the market until the controversial products win approval from FDA regulators, in an attempt to make the products less available to young consumers.

In the statement, Juul officials said the company will be “refraining from lobbying the administration on its draft guidance” that proposes banning fruit-flavored vaping products, unless approved by the FDA.

Apology for Teen Addiction

On July 15, Juul Labs CEO Kevin Burns issued an apology to parents of children who have become addicted to vaping products made by the company. Aired on a CNBC documentary, “Vaporized: America’s E-cigarette Addiction,” Burns’ apology was followed by the explanation that vaping products were never meant for teens. “First of all, I’d tell [parents] that I’m sorry that their child’s using the product,” said Burns. “It’s not intended for them. I hope there was nothing that we did that made it appealing to them.”

According to the company, Juul’s vaping products are intended for adults who are trying to quit smoking. Last year, however, approximately three million high school students in the U.S. used these products. Whether the dramatic rise in teen vaping is an unintended consequence of introducing this new type of product to the market or a consequence that, at least, could have been predicted, given an advertising campaign that uses social media platforms popular among teens, the FDA has called it an epidemic.

Filed Under: Online Exclusives Tagged With: e-cigarettes, vaping

You Might Also Like:

  • COSM 2012: TRIO Guest of Honor Cautions against Physician Advertising
  • Pathology of Lung Disease Linked to Vaping
  • FDA Recalls Zantac
  • EMR and Advertising: Strange Bedfellows?

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Have you invented or patented something that betters the field of otolaryngology?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • A Journey Through Pay Inequity: A Physician’s Firsthand Account

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Keeping Watch for Skin Cancers on the Head and Neck

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Physician Handwriting: A Potentially Powerful Healing Tool
    • Leaky Pipes—Time to Focus on Our Foundations
    • You Are Among Friends: The Value Of Being In A Group
    • How To: Full Endoscopic Procedures of Total Parotidectomy
    • How To: Does Intralesional Steroid Injection Effectively Mitigate Vocal Fold Scarring in a Rabbit Model?

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939